- Conditions
- Secondary Hyperparathyroidism
- Interventions
- Teriparatide
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 40 Years to 59 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 84
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
- Interventions
- CTAP101 Capsules, CTAP101 Injection
- Drug
- Lead sponsor
- OPKO IP Holdings II, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 12
- States / cities
- Peoria, Arizona • Evergreen Park, Illinois • Springfield, Massachusetts + 9 more
- Conditions
- Osteopenia, Renal Osteodystrophy
- Interventions
- pamidronate
- Drug
- Lead sponsor
- US Department of Veterans Affairs
- Federal
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Secondary Hyperparathyroidism, End Stage Kidney Disease
- Interventions
- PLS240, Placebo, Open-Label Extension PLS240
- Drug
- Lead sponsor
- Pathalys Pharma
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 412 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 50
- States / cities
- Anaheim, California • Chula Vista, California • Escondido, California + 43 more
- Conditions
- Secondary Hyperparathyroidism Due to Renal Causes, Vitamin D Insufficiency, CKD Stage 3, CKD Stage 4
- Interventions
- Calcifediol Oral Capsule, Calcifediol Oral Product, Cholecalciferol, Paricalcitol Oral Capsule
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 3
- States / cities
- Garden Grove, California • Chicago, Illinois • West Bend, Wisconsin
- Conditions
- Kidney Disease
- Interventions
- Vitamin D, Placebo
- Dietary Supplement · Other
- Lead sponsor
- Atlanta VA Medical Center
- Federal
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Secondary Hyperparathyroidism, Chronic Kidney Disease
- Interventions
- Cinacalcet
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Tucker, Georgia • Baltimore, Maryland + 15 more
- Conditions
- Secondary Hyperparathyroidism, Chronic Kidney Disease
- Interventions
- Cinacalcet, active vitamin D analogue
- Other
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Lynchburg, Virginia
- Conditions
- Secondary Hyperparathyroidism, Hypocalcemia
- Interventions
- Calcitriol
- Drug
- Lead sponsor
- Roxane Laboratories
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Springfield, Missouri
- Conditions
- Secondary Hyperparathyroidism, Chronic Kidney Disease
- Interventions
- Etelcalcetide, Cinacalcet, Oral Placebo, Intravenous Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 683 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 41
- States / cities
- Azusa, California • Bakersfield, California • Chula Vista, California + 37 more
- Conditions
- Chronic Kidney Disease, Secondary Hyperparathyroidism, Chronic Renal Insufficiency, Chronic Renal Failure
- Interventions
- CTAP201 Injection, Doxercalciferol
- Drug
- Lead sponsor
- OPKO IP Holdings II, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 6
- States / cities
- Peoria, Arizona • Springfield, Massachusetts • Cincinnati, Ohio + 3 more
- Conditions
- Parathyroid Tumor, Primary Hyperparathyroidism, Secondary Hyperparathyroidism (SHPT), Tertiary Hyperparathyroidism
- Interventions
- Not listed
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 839 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2032
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Secondary, Secondary Hyperparathyroidism
- Interventions
- Cinacalcet
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 28 Days to 2190 Days
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Francisco, California • Louisville, Kentucky + 1 more
- Conditions
- Hyperphosphatemia
- Interventions
- Niacinamide
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Secondary Hyperparathyroidism
- Interventions
- Hectorol (doxercalciferol injection), Zemplar (Paricalcitol injection)
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Kidney Failure, Secondary Hyperparathyroidism, Hyperphosphatemia, Hypercalcemia
- Interventions
- Calcitriol, Paricalcitol
- Drug
- Lead sponsor
- Winthrop University Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Mineola, New York
- Conditions
- Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, Vascular Calcification, Hyperparathyroidism; Secondary, Renal
- Interventions
- Etelcalcetide
- Drug
- Lead sponsor
- Thomas Nickolas, MD MS
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Kidney Disease, Hyperparathyroidism, Hyperparathyroidism, Secondary, Kidney Disease, Secondary Hyperparathyroidism
- Interventions
- cinacalcet capsule, placebo, Standard of Care
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 14 more
- Conditions
- Secondary Hyperparathyroidism, Chronic Kidney Disease
- Interventions
- Paricalcitol, Calcitriol
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Evanston, Illinois • Detroit, Michigan + 1 more
- Conditions
- Secondary Hyperparathyroidism
- Interventions
- Hectorol® (doxercalciferol capsules), doxercalciferol capsules, Hectorol®, doxercalciferol capsules, Hectorol® capsules
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 8
- States / cities
- Hot Springs, Arkansas • Downey, California • Tarzana, California + 5 more
- Conditions
- Chronic Kidney Disease, Vitamin D Deficiency
- Interventions
- Cholecalciferol, Placebo
- Drug
- Lead sponsor
- Atlanta VA Medical Center
- Federal
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Coronary Artery Disease, Chronic Kidney Disease, Hypovitaminosis D, Secondary Hyperparathyroidism
- Interventions
- paricalcitol, placebo
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Secondary Hyperparathyroidism, End-Stage Renal Disease
- Interventions
- Paricalcitol, Calcitriol
- Drug
- Lead sponsor
- AbbVie (prior sponsor, Abbott)
- Industry
- Eligibility
- Up to 16 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Gainesville, Florida • Orlando, Florida + 15 more
- Conditions
- Secondary Hyperparathyroidism-Chronic Kidney Disease
- Interventions
- Doxercalciferol (GZ427397), Calcitriol
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 17 more